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Abstract - Rasum6 - AHHOT~UHR - esumen 
RARE EARTHS AND RUTHENIUM: METABOLISM AND REMOVAL FROM THE MAMMALlAN BODY. The 
effectivenesr of a chelating agent in removing an intemally depmited radiometal is essentially determined by: 
(i) its affinity toward the radiometal as related to the competition of endogenous cations and ligands; (ii) the 
velocity by which the exchange reaction between therapeutic and endogenous ligands proceeds. 
The limitation of the therapeutic effect due to the last mentioned factor is exemplified by experimental 
data with radiomthenium. Although the chelation of mthenium by several compounds. panicukrly the 2:2'-bis 
[di(carboxymethyl) aminoethylthio] ethane. exceeds markedly the binding affinity of proteins, the mobi- 
lized fractionis small because of the exuemely sluggish dissociation of the nithenium-protein complexes. 
On the other hand, a very high mobilization of radiocerium is guaranteed by iu fast CO-odination re- 
actions. provided that suitable chelaton are chosen. Suuctural factors detetmining the relative chelate stability 
are discussed. Ligands with a pronounced polydentate s m c ~ r e .  e. g. diethylenetriaminepentaacetic acid and 
triethylenetetraaminehexaacetic acid. proved to be most effective. Experimental data are presented allowing 
one to work out the optimal dcsage schedulr which is the parenteral administration of only a few medium 
doses, separated by several treament-free days. 
TERRES RARES ET RUTHENIUM: METABOLISME ET E L ~ ~ I N A T I O N  CHEZ LES MAMMI~%Es. L'effica- 
citd d'un agent de  chelation dans I'6liminarion d'un radiomßtal ddpose a I'intbrieur de  l'organisme est deter- 
min6e essentiellement a) par son affinite p u r  le radiometal par rappon a celle des cations endogenes e t  des 
coordinats; b) par la vitesse a laquelle s'opere la rhction d'bchange entre coordinau thdrapeutiques et endo- 
genes. 
La limitation de l'effet thdrapeutique due au deuxieme facteur est illusu& par des d o m h  exp5rimen- 
tales sur l e  radioruthenium. Bien que la chelation de Ru par plusieuts compos&, notamrnent le 2 :2'-bis [di 
(carboxymethyl) amin&thylthio]-Ethane excede notablement l'affinite? des proteines. la fraction mobilMe 
est faible en raison de  la dissociation ex r rhemen t  faible des complexes Ru-prot6ines. 
D'un auue c6td. une mobilisation ~I&S  6levee du radioc+5rium est assude par ses nkctions rapides de  
coordination, a condition de choisir des agents de chelation appropries. Les auteun duzdient les facteurs s w c -  
turaux qui determinent la stabilit6 relative du produit de chdlation. Les cwrdinau caractdrisds par Une SWUCNI'e 
prononc& de polydentate. tels que l 'adde didthyleneuiamine penta-acdtique e t  I'acide tribthylenet6tra- 
amine hexa-acdtique. se sont 16v6lds les plus efficaces. Le memoire contient des donnees exp4rimentales qui 
pemettent d'blaborer l e  plan de  dosage optirnum. qui consiste dans l'administration parenterale d'un petit 
nombre de  dcees moyennes. avec des intewalles de  quelques jours pendanr lesquels aucun traitement n'est 
appl iqd.  
PEWME 3EMJlM M P Y T M :  METAEOJMJM M YIiAJiElME M3 OPrAHMSPIA MJIW(OMTADiiEr0. W e x r n e n o c ~ b  
enyrpnnounnencnux coennnennd npn ynanannn ornoxn~mnxcn B opranmue pannoa~~nexux lneuexroa onpe- 
nenaerca a )  npovnooTbn x~~unuec~o i i  C B ~ W  C pannoa~rnanrni veranmou ~(o~nomennn K nonnypnpyxaqeuy 
CPenCTBY 3 ~ n o r e n ~ u x  KaTnonoB n annexn n 6) caopocrbn. c ~ozopoR nporenaeT peaxunn o6uena ueury 
~ e P a n e ~ r u v e c ~ n u  n annoren~uun annennaun. 
Orpa~nvenxoc~b repanearnvec~oro neticrsnn dnaronaps nannvno Oaxropa 6) neuoxcrpnpye~cn c 
nOu019bD J K C ~ ~ P M Y ~ ~ T I U I ~ H Y X  nannbu C paanopyrenneu. Xorn novnneacnpyman cnocodnocrb WenMn c 
neKor0proln nounne~coo6pa3o~arenawn, B ocodennocrn c 2:2 bnc ~nw(~ap6o~cue~nn)avn~o~rnnrnoj ara- 
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H O U .  ~ ~ a v n r e n b ~ o  n p e ~ o c x o n u r  npovxocrb C B P J H  nporeunos C py~enueu,"pac~sopnuan" iDpaawn uana 
BBUIIY ncKmuwrenbno nennexnoti nnccowauun nounnerccoa Ru-nporenx. 
B r o  xe apeun ovenb donbman pacrsopnnocrb pannouepnn odecnevnsaercn 6ncrporoti KOUnJIeKco- 
06paJOBanHn npn ycnosnn andopa c o o r s e r c r s ~ x  s~yrpuKonnneKcH~ coenwnexnfl. OdCylnamCR C T m -  
rypiüie iDmropu. o n p e n e n n w e  o r ~ o c n r e n b ~ p  c r o i 7 ~ o c r ~  Kounnencoa. Annennu C w ~ e e c r x d l  nomneHrnu- 
ao# c r m r y p o t t .  nanpauep, nuirnnenosan rpnaunnone~rayitcyc~an Kmcnora n r p ~ ~ r u n e ~ o ~ a n  rerpaaunxo- 
rercayxcycnan nncnora nsnnmrcn naudonee ~ & ~ D ~ K T H B H Y Y H .  i ipsonarca  3 ~ c n e p n u e ~ ~ a ~ 1 b ~ n e  nannue, no3- 
sanspisrie eupaoorarb onrnuanbxnü nopnnox ItO3UpOBKU. noroputl npencraamner codoi7 napenrepansxoe 
asenenne s c e r o  necxonbnmx cpennux n o ~  v e p e l  onpenenenxue nponeryrm epeuexn.  
TIERRAS RARAS Y RUTENIO: METABOUSMO Y ELIMINACION DEL CUERPO DE LOS MAM~FEROS. La 
eiicacia con que un agente de quelaci6n elimina un metal radiactivo depoaitado intemamente depende. ante 
todo, de a) su afinidad por e l  metal. en relaci6n con la competencia entre los cationes y los ligandos end6- 
genos. b) la velocidad con que se produce la reacci6n de intercambio entre los ligandcs teraguticos y end6- 
genos. 
Ejemplo del Umite que impone al efecto teragutico este iIltimo factor son los datcs obtenidos experi- 
menraimente con radiomtenio. Aunque e l  poder de  quelaci6n de  diversos compuestos. panicularmente e l  
2.2.-bis [di(carboximetil) aminoetiltio] etano. por e l  Ru supera considerablemente a la  afinidad d e  las 
pmtelnas por dicho metal, la fracci6n movilizada es pequena porque los complejos Ru-proteina se  disocian 
rnuy lentamente. 
En cambio. la movilizaci6n de radiocerio es muy elevada cuando se eligen agentes de quelaci6n adecua- 
dos porque sus teacciones de coordinaci6n se verifican con rapidez. La memoria discute los factores estmc- 
mrales que determinan la estabilidad relativa de los quelatos. Se encontr6 que los ligandos que poseen una 
etmicnira muy ramificada. por ejemplo, 1- icidos dietilenuiaminopentaac&tico y trietilentraaminohexa- 
a d t i c o  son los m i s  eficaces. Los autores presentan resultados experimentales que permiten determinar la 
posologfa 6ptima. que consiste en administrar parenteralmente algunas dosis medias. con intervalos de varios 
di;u. 
The use of chelating agents has been proved to be the most promising 
approach to the problem that mainly concerns this meeting: radioactive metal 
mobilization. The Progress achieved during the last decade in the application 
of chelating agents i s  well known [ I ]  and there i s  no need to emphasize their 
effectiveness once again. On the other hand, however, it should not be over- 
looked that there are  essential drawbacks and limitations to the therapeutical 
applicability of chelating compounds. This i s  particularly true of the often 
questionable results with delayed treatment. 
Primarily, there a r e  three factors which determine the effectiveness 
of a given chelator: 
(i) The velocity of the reactions involving the exchange of the radiometal 
between endogenous ligands (or  other biological acceptors) and the thera- 
peutical chelating agent. If this exchange is sluggish and the velocity i s  slow, 
in comparison with the velocity at which the chelate is excreted from the 
organism, the fraction of the radiometal mobilized from the t issues will 
be negligible . 
(ii) The affinity of the chelator to the radiometal should be a s  high a s  
possible in order  to achieve the maximum effect. In determining the ef- 
fectiveness, the competition of endogenous cations (calcium and hydrogen 
mainly) and of endogenous ligands o r  ion-exchangers competing with the 
chelator for  the radiometal must be taken into account. 
(iii) It frequently turns out to be necessary to administer the chelating 
compound repeatedly because a single dose does not give a satisfactory 
mobilization effect. In this case, we may face the limit set  up by the toxic 
side effects of the chelator. 
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This paper is an attempt to corroborate these Statements by experi- 
mental findings and also to present some preliminary data bearing on the 
last-mentioned point; i. e.  the working out of a treatment schedale which 
guarantees a maximum therapeutic effect and simultaneously avoids harmful 
side-effects. 
The practical significance and potential hazard of RU"' i s  emphasized 
by numerous investigations concerned with i t s  metabolic behaviour and 
radiotoxicity [2 - 71 . It i s  somewhat surprising, therefore, that the possi- 
bilities of i t s  removal from the body have not been the subject of experi- 
mental studies so far. This rnay be the result of the rather involved chemistry 
of ruthenium, a s  well a s  of the unavailability of quantitative data dealing 
with the CO-ordination tendencies of ruthenium [8] . 
In order to find effective compounds, it was necessary to include into 
the Screening tests a s  many structurally different compounds as  possible: 
Several polyaminopolycarboxylic acids, polyamines, sulfhydryl- containing 
compounds, condensed phosphates, as well as  agents used in classical analy- 
t ical chemistry (such a s  rubeanic acid, phenantroline, dipyridyl) were 
tested. In order  to  get the maximum effect the compounds were injected 
intravenously and simultaneously with Ru1' chloride o r  nitrosyl nitrate.  
The detailed results will be discussed in a la ter  publication [SI . Here, it 
may suffice to  mention that the most pronounced reduction of Ru1'' depo- 
sition in the tissues was achieved by l:2-Bis-[2-di(carboxymethy1)amino- 
ethylthio] ethane (BATE): 
HOOC-H2 C, 
/ 
CH2 - COOH 
N-(CH2)2 -S-(CH2 )2 -S-(CH2 )2  - N  
HOOC-H, d ' CH, - COOH 
The superiority of BATE over diethylene-triamine-pentaacetic acid (DTPA) 
and over the analogous compound possessing ether oxygen instead of sulphur 
as heteroatoms emphasizes the participation of the sulphur atoms in chelating 
ruthenium . 
The influence of BATE on the metabolic behaviour of Ru106 may be 
characterized by Figs. 1 - 5. Whereas R U ' O ' C ~ ~  (dissolved either in water 
o r  in blood serum) i s  retained by the blood over a relatively long period, 
the Ru-BATE chelate i s  cleared from the blood rather quickly (Fig. 1). Fig. 2 
compares the retention of the different ruthenium forms by the liver; the 
approximately tenfold lower deposition of the ruthenium chelate was also 
obtained with the other Organs and tissues. The chloride, a s  well as  the 
chelate, are  excreted mainly in the urine (Fig. 3 ) .  Noteworthy i s  the reduced 
effectiveness af BA'IE in preventing the deposition of  RU"^ administered 
a s  nitrosyl nitrate (Fig. 4 ) .  
In view of the exceedingly slow blood clearance of RulO\ a fairly high 
effectiveness for  the separate and delayed administration of BATE could 
be anticipated. It was, therefore, unexpected and highly surprising to note 
that BATE, eveh when injected immediately after  RU"^, proved to bealmost 
without any effect (Table I).  Neither the faecal nor  the urinary excretion 
ra tes  were significantly affected by a six-times-repeated administration 
of the chelator (Fig. 5) and it may be pointed out that identical negative results 
were also obtained with other chelating compounds [9] . 
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Fig. 1 
qlearance of ~u'Ok1,  (dissolved in watet. S e m ,  or in 10-' molar Na,-BATE. 
and injected i .  V.)  from the blood 
Each point is the mean average of 5 rau 
o RU-CL~ 1 ' . RU-CL~ IN SERUM 
0 01 
X) X,? 10) Y)' 1 
min 
Fig. 2 
Retention of RU''' Cl, by the llver 
SeeSee Fig. 1 
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d 1 2 3  1 2 3  
URINE FAECES 
Fig. 3 
Excretion of  RU''^ Cls (dissolved in water or 10" molar Naz-BATE. and injected i. V.) 
Each point ir the mean average of 6 rars 
Fig. 4 
Effect of 50 ph4 Na,-BATE (sirnultaneous L. V. injection) On the 
distribution of ~u'' -Chloride and RU" ' - n i e 1  nitrate 
5 rao per group 
We are  able to corroborate this obvious discrepancy by in vitro studies. 
It was shown by electrophoretic techniques that the slow clearance of  RU"^ 
from the blood is due to i ts  binding by all protein fractions of the plasma. 
It must be assumed that the stability of the protein complexes i s  lower than 
that of the Ru-BATE chelate; this is exemplified by the fact that Ruzo6 , if 
added to a BATE solution in Serum, migrates almost entirely as  the chelate, 
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CONTROL 
--- 6 x M p M  BAT€ 
Fig. 5 
Effecu of Na2 -BATE on the excretion of i. V. injected ~ u ' " ~ ' C 1 ~  
3 rats per group. 
whereas the activity of the protein fractions remains negligible. However, 
if BATE i s  added to serum already containing RU"= , the fraction withhigher 
activity remains bound by the proteins, Even if the serum i s  kept for several 
days before the electrophoretic separation, the amount of ~ u ~ O b e m o v e d  
by BATE from the proteins increases only slightly. Consequently, we have 
to conclude that the ruthenium-protein complex represents an "inert co- 
ordination" compound which is characterized by an extremely slow dis- 
sociation. By analogy with the CO-ordination chemistry of meta1 ions of the 
platinum group, it i s  likely that the formation of predominantly covalent 
bindings is the responsible factor. 
It is easy to understand why the chelators a re  alrnost ineffective when 
they a r e  given after the administration of R u I O ~  , that is after the formation 
of ruthenium association compounds with the serum and tissue proteins. 
Likewise, it explains the reduced chelate effectiveness in mobilizing RulU6 - 
nitrosyl nitrate, in which case a preformed ruthenium complex is involved. 
In contrast with ruthenium, the exchange reactions of cerium a re  re- 
latively fast. It is possible, a s  will be Seen later,  to remove significant 
amounts of radioceriurn from the body by suitable chelating agents, even 
if the treatment is started with marked delay. We have pointed out at the 
outset that a necessary prerequisite for a high effectiveness of a chelator 
is its relative chelate stability, i,e. i ts  stability relative to the competition 
of endogenous cations, especially calcium. The cerium(II1) ion has a co- 
ordination requirement of eight, whereas calcium (11) possesses a CO-ordination 
number of only six. Consequently, the stability constant of a cerium 
chelate is influenced by the number of electron-donor atoms of the iigand 
to a higher extent than that of the calcium chelates. Likewise, the biological 
effectiveness of chelators increases with increasing number of ligand atoms 
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EDTA 
NUMBER CF LGAND ATOMS 
Fig. 6 
Effect of several polyarninopolyearboxylic acids (injected i .  p. after 2 min) 
on the retention of i .  V. injected cel" Cl, by the Organs of the rat 1151 
be applied unlimitedly. The ten-dentate triethylene-tetraamine-hexaacetic 
acid (TTHA), i t  is true, gives r ise to a higher reduction of the skeletal 
deposition of celU than the eight-dentate DTPA, not to speak of the six- 
dentate ethylene-diamine-tetraacetic a ~ i d  (EDTA). The retention of ce l@ 
by the liver, however, is affected by TTHA to a lesser  degree. The next 
higher homologue, the twelve-dentate tetraethylene-pentaamine-heptaacetic 
acid (TPHA), proves to be inferior to DTPA with regard to G Organs. It 
seems likely that this loss in effectiveness is caused by, the formation of 
less  stable bimetallic and possibly polymerizing chelate species. It may 
be mentioned in this context that the order of effectiveness of the different 
chelating agents quoted in Fig. 6 also holds for other metal ions with higher 
CO-ordination requirements, such a s  Yttrium, thorium, plutonium, and 
americium [I] . 
Let us now turn to the dependence of chelate effectiveness on several 
essential parameters. Since the enteral absorption of DTPA and related 
compounds. is relatively low, a parenteral route of application is usually 
preferred. However, considering the relatively high effectiveness of even 
smaii doses of DTPA [I] , as  weii a s  the practical advantage offered by 
oral administration, the possibility of using this route should not be neglected 
entirely. As a matter of fact, numerous investigations [I0 - 121 havedemon- 
strated unequivocally a quite satisfactory mobilization of different radio- 
metals by oral DTPA. In addition, one gains the impression from some of 
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these studies that the effectiveness of oral DTPA might be higher than ex- 
pected from the experimentaliy determined value for  the absorption from 
the intestinal tract. Properly considered, a higher effect might be expected 
if it is tentatively assumed that orally administered chelator absorbed from 
the gut reaches higher concentrations in the l iver  than it would following 
intravenous injection. In order  to elucidate this point, we compared the 
effectiveness of a dose of 50 PM DTPA applied intraperitoneaily with that 
of 1000 PM administered oraily. The chosen ratio of doses is based on the 
fact that the enteral absorption of DTPA is approxirnately 5% [13] . As can 
be Seen from Table LI, both application routes give an almost identical effect; 
the slight apparent superiority of oral DTPA does not reach statistical sig- 
nificance. 
TABLE I1 
EFFECT OF ORAL CHELATE DOSES ON THE RETENTION OF 
C e i 4 4 C 1 3  BY THE ORGANS OF THE RAT 
Mean average f S. E. 
No.1: 7 animals per group, sacrificed on day 6. Chelates were administered 
on the 3rd day after the intravenous injection of Ce144 . 
No.2: 10 animals per group, sacrificed on day 4. Chelates were administered 
24 h after the intravenous injection of Cel44. 
Recently it was claimed by BALLOU [10] that the superiority of TTHA 
over DTPA in removing internally deposited plutonium becomes still more 
pronounced if  the chelators are given by the oral route. In a similar experi- 
7 
ment with Ce144 , however, we were not able to confirm this observation. 
As  can be seen from the datapresented in Table 11, a higher amount of ~ e ' ~ ~  
is removed by DTPA. This holds for the 1:l-Ca-TTHA chelate a s  well as 
for a molar ratio of 2 Ca : 1 TTHA. Both chelate species differ inthe number 
of their negative charges which in turn couid be reflected by different enteral 
Treptment 
Control 
1 rnM DTPA p.0. 
0.05 m M  DTPA i. p. 
Conuol 
' 0.25 mM Ca-DTPA p. 0. 
" Ca-- " 





As to the final conclusions about the feasibility of ora l  treatment, it 
should not be overlooked that fairly high doses of DTPA (such a s  those used 
in our experiments) result in severe diarrhoea and certain mortality. 
% of Ce'& dose 
Liver 
35.5 t 1.39 
21.1 t 1.84 
23.3 t 1.39 
32.5 i 0.76 
21.8 t 0.69 
25.2 i 1.07 
23.8 i 2.58 
Kidneys 
0.93 t 0.05 
0.73 i 0.06 
0.82 i 0.05 
1.61 i 0.11 
1.44 i 0.14 
1.38 i 0.09 
1.19 i 0.04 
Skeleton 
23.5 t 0.69 
17.3 i 0.91 
19.7 i 0.70 
26.2 t 0.76 
22.7 i 0.91 
21.9 i 0.50 
20.9 i 0.51 
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I t  was mentioned previously that the effectiveness of a given chelator 
depends essentially on the s t ab i l i t~  of the binding of the radiometal by endo- 
genous constituents. Since these.stabilities a r e  reflected by the "biological 
half-time", it follows that the extent of radiometal mobilization by a chelator 
should be inversely proportional to the biological half-time and in the event 
of a multi-exponential retention function, the mobilization should decrease 
progressively with time. 
Initially about 40 to 5070 of cel& is retained by the liver,  the l a rge r  
fraction being excreted fairly quickly with a half-time of a few days [14] . 
A ciear diminution of the excretion rate becomes manifest only after alapse 
of several  weeks. In keeping with this behaviour, the effectiveness of a 
single DTPA dose remains constant over a period of 3 - 4 weeks and the 
relative amount of ~e~~~ removed decreases only when the departure from 
exponential linearity, referred to  above, becomes manifest. The higher 
effectiveness noted with very early administration of DTPA is because short- 
ly  af ter  injection the distribution of ~e~~~ has not yet reached equilibrium 
and an essential and easily removed fraction is st i l l  in the extraceiiular 
space. In the case of the kidneys (retaining approximately 2% of the ce14 
dose) a higher fraction, comprising about 5070, is bound rather tightly and 
retained with a half-time of at least 200 d, Correspondingly, thedependence 
of DTPA effectiveness on the time of i ts administration is much more pro- 
nounced than in the liver. The Same is true for the skeleton; this is in keep- 
ing with the fact that the amount of Ce144 retained by the bones (20 - 30%) 
remains constant over a longer period of t ime. 
If these time dependence data a r e  considered, one might expect that 
with prolonged treatment with o r  without an increase of chelate dose, a 
point will be reached where the Organs o r  Organ compartments containing 
the easily removable radiometal fractions a r e  depleted and that a further 
increase of the total chelate dosage would not give r ise  to a corre'spondingly 
higher mobilization effect. In order  to test and verify these assumptions, 
rats were injected with Ce144 and received three doses of DTPA whichvaried 
by a factor of 100; the treatment was started either on the 7th o r  on the 
31st day. As can be Seen from Table 111 and Fig. 7 the l iver  shows only a 
slight departure from linearity at the highest dose, indicating that the postu- 
lated "saturation" level of effectiveness i s  not yet reached. As to the removal 
of celM from the skeleton, there i s  clear linear regression of effectiveness 
with dose for  early treatment, whereas in the delayed treatment ser ies  the 
effect remains constant over a relatively wide range of dosage. Thus, we 
gain the impression that at  this stage already 8070 of the skeletal ~e~~~ is 
withdrawn from equilibrium and no longer accessible to the chelating agent. 
A similar indication is given by the fact that the superiority of TTHA over 
DTPA observed with early treatment (Fig. 6)  is completely nuiiified when 
both compounds a r e  given after some delay [15] . 
A somewhat unexpected behaviour i s  to be seen with regard to the kidneys 
(Fig. 7 and Table III), namely,-the decrease of effectiveness of DTPA at 
higher dose levels. The Same situation was also encountered in  another 
experimental s e r i e s  (No. 3 in Table 111 and Fig. 8), in which the s ize  of a 
single dose of DTPA (amounting to  200 p M  per  animal) was kept constant, 
whereas the number of doses were varied from 1 to 6. DTPA was given 
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EFFECT OF DLFFERENT DTPA TREATMENT SCHEDULES ON THE 
RETENTION OF INTRAVENOUS INJECTED Ce144C13 BY THE ORGANS 
OF THE RAT 
Mean average f S. E. 
No. 1 : 16 animals per  group, sacrificed on day 19. 
No. 2: 8 animals per  group, sacrificed on day 42. 
No. 3 : 6 animals per  group, sacrificed on day 42. Na3Ca-DTPA was admi- 
nistered in ali ser ies  intraperitoneaily. 
On every 4th day and the animals of all experimental groups were sacrificed 
on the 42nd day after administration of cel* . In spite of the marked scatter- 
ing of the experimental points, there is a clear and significant decrease 
of kidney effectiveness with increasing number of DTPA doses. Furthermore, 
i t  should be emphasized that in the case of high total doses the variability 
within any one group is  significantly higher than for low dose levels or  other 
Organs. If the wen-known nephrotoxicity of the polyamino-polycarboxylic 
acids is taken into account, a plausible tentative assumption might be that 
the loss in effectiveness noted at high dose levels is caused by an impairment 
of the renal excretion functions. As for the dose-dependence of the effective- 
ness in liver and skeleton, the results summarized in Table III and Fig. 8 
agree in essentials with the previous experiment presented in Fig. 7.  
In all the above experiments, the interval between individual DTPA 













1 i!: 28 
200 20. 24, 28, 31 
20. 24. 28, 31. 35 
20. 24, 28. 31. 35. 38 
% of Ce dose 
liver 
8.11 i 0.61 
6.04 t 0.42 
4.52 i 0.19 
3.25 i 0.22 
1.82 t 0.11 
1.75 I 0.20 
1.70t  0.19 
1.63 i 0.28 
1.54 i 0.26 
1.56 i 0.17 




0.39 i 0.018 
0.34 t 0.017 
0.29 i 0.014 
0.30t0.016 
0.3710.016 
0.30 t 0.015 
0.31 i 0.024 
o .n to .021  
0.24i0.021 




19.6 i 0.40 
18.6 t 0.41 
17.3 t 0.37 
16.4t0.34 
14.4t0.39 
21.9 i 0.87 
19.6 t 0.47 
i 9 . 4 t o . s  
17.7i0.49 
.17.7 i 0.79 
17.410.29 
. See experiment No. 2 
1.46 i 0.12 
1.31 t 0.070 
0.80t 0.034 




0.19 t 0.018 
0.21 i0.017 




19.3 t 0.99 
17.0t0.24 
15.7 t 0.51 
17.7i0.59 
16.9i0.82 
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0 3 DTFU DDYS ON WY 
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Fig. I 
Dependence of DTPA effectiveness on d a e  
Experimental series No. 1 and 2. Table 111; calculated after logarithmical transfonnation 
extent the effectiveness of the chelator i s  affected by the length of the treatment- 
free interval, the rats were given three doses of 200 pM.DTPA, either daily 
o r  on every 4th day and the treatment was started on the 3rd o r  on the 40th day 
after injection of c ~ ~ ~ .  As can be Seen from the data of Fig. 9, theeffective- 
ness  of both treatment schedules was identical with i-egard t o  kidneys and 
skeleton. In the case of the liver, however, the narrowly spaced multiple 
doses proved to be less effective; the differences are  statistically significant. 
This finding agrees with and i s  explained by the observation of several in- 
vestigators [14, 16 - 191 that the action of highly effective chelators such 
as  DTPA i s  sustained over several days and is mainly confined to the mobili- 
zation of radiometals from the liver.  It may be deduced that a protracted 
administration of a given chelator affords a better "utilization" of the effect 
of each single dose, at least if we a r e  dealing with "liver-seeking" radio- 
nuclides . 
In addition, a protracted treatment schedule might prove to be favour- 
able from another point of view, namely, in avoiding toxic and harmful side 
effects of the chelator. Our present knowledge of the toxicity of chelating 
agents belonging to the group of synthetic polyarnino-polycarboxylic acids 
may briefly be outlined a s  follows. It has been learned with experimental 
animals, as  well a s  by clinical experience. that repeated administration of 
sufficiently high chelate doses can give rise to severe (although in principle 
reversible) darnage to renal functions and morphology, i. e. nephrotic changes 
[13, 201 . Whereas in the case of EDTA, a compound which in the lastdecade 
has found wide experimental and clinical use, the order  of magnitude of the 
toxic dosage may be regarded a s  adequately established. the quantitative 
aspects of DTPA toxicity a r e  still rather vague. The acute toxicity of EDTA 
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Dependence of DTPA effectivenw on nurnber of doses 
Experimental series No. 3. Table 111; calculated after logarithmical uamformation 
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Fig. 9 
Removal of i. V. injected ce lA4  CS by DTPA f m  ihe orgam 
10 rau per group 
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Fig. 10 
Toxicity of Na2Ca-EDTA and Na, Ca-DTPA (i. p. injection) in rau 
20 animals per group 
and DTPA administered as  a single dose is alrnost identical [ l l ]  , but the 
Same i s  not necessarily true of the toxicity and long-term effects of multiple 
chelate doses. We have recently begun a detailed study aimed at elucidating 
this question, but the experiments are  still far from completion at the present 
and only preliminary data are available. Fig. 10 shows time-mortality curves 
for  rats  which received a total of 30 chelate doses intraperitoneally, each 
of them arnounting to 2 . 5  mM Na2 Ca- EDTA, o r  Na3 Ca-DTPA per  kg . The 
injections were given either daily o r  on every 4th day. The comparison of 
the two daily-treatment ser ies  shows that, on a molar base, DTPA is ap- 
proximately 3 to  5 times more toxic than EDTA. In this context i t  may be 
mentioned that FOREMAN et al. [21] observed nephrotic lesions with rela- 
tively low doses of DTPA (ineffective in the case  of EDTA). The second 
important result of this experiment (Fig. 10) is that the protracted treatment 
schedule proves to be less harmful. Because of the limited number of animals, 
however, statistical significance i s  reached only for the DTPA groups. The 
question of why the time-effect curves appear to be truncated, even when 
the time CO-ordinate is logarithrnically transformed, is stil l  unanswered. 
In other words, i t  is not yet fully understood why a certain proportion of 
anirnals appear to be completely unaffected by relstively high total dosage 
In summarizing our experimental data and considerations. we may draw 
the following conclusions: 
(i) R U ' O ~  is chelated by different compounds, in particular by BATE, 
rather efficiently. Nevertheless. the practical value of all chelating agents 
is minimal, since exchange reactions of ruthenium between exogenous and 
endogenous ligands proceed too slowly by orders of magnitude to guarantee 
a sizable mobilization effect. 
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(ii) A marked removal of internally deposited ~e~~~ can be achieved 
by appropriate chelating agents, even when treatment is started with delay. 
At the present stage of our knowledge, DTPA and TTHA should be the com- 
Pounds chosen for therapeutical purposes. 
(iii) Experimental data a r e  presented on the toxicity of DTPA and the 
dependence of i ts effectiveness on dose, time and mode of administration. 
They permit recommendation of a treatment schedule which guarantees a 
maximum therapeutical effect and simultaneously avoids harmful side-effects 
of the chelator. According to this schedule the treatment should be started 
a s  early a s  possible, the number of individual doses should be relatively 
lirnited and the size of the individual doses should lie in the moderate range, 
since an unlimited increase of the total dosage is not followed by a cor-  
respondingly higher effect. In contrast to the prevailing practice of daily 
o r  even twice-daily administrations of the chelating agents, a more effective 
and less  harmful schedule i s  to be preferred, the essence of which is that 
each individual chelate dose is followed by several  treatment-free days. 
(iv) Although these conclusions and recommendations a re  in detail only 
valid for  radiocerium and other r a r e  earths,  preliminary data On other 
radiometals (such as  plutonium o r  americium) indicate that, at  least in 
principle and with only minor corrections, they hold for other radiometals 
as  well. 
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